Document is current
Any future updates will be listed below
-
Authors
Cummings, Jeffrey L. https://orcid.org/0000-0001-8944-4158
Zhou, Yadi
Van Stone, Alexandra
Cammann, Davis
Tonegawa-Kuji, Reina https://orcid.org/0000-0001-7998-939X
Fonseca, Jorge https://orcid.org/0000-0001-7917-5169
Cheng, Feixiong https://orcid.org/0000-0002-1736-2847
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (P20GM109025)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R35AG71476; R25 AG083721-01;)
Alzheimer's Disease Drug Discovery Foundation; Ted and Maria Quirk Endowment; Joy Chambers-Grundy Endowment.
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (RF1NS133812)
Alzheimer's Association (ALZDISCOVERY-1051936)
- License Information
-
More Information
Article History
Received: 17 April 2024
Accepted: 24 January 2025
First Online: 19 February 2025
Competing interests
: J.C. has provided consultation to Acadia, Acumen, ALZpath, Axsome Artery, Biogen, Biohaven, Bristol-Myers Squib, Eisai, Fosun, GAP Foundation, Janssen, Karuna, Kinoxis, Lighthouse, Lilly, Lundbeck, LSP/eqt, Merck, MoCA Cognition, New Amsterdam, Novo Nordisk, Optoceutics, Otsuka, Oxford Brain Diagnostics, Praxis, Prothena, ReMYND, Roche, Scottish Brain Sciences, Signant Health, Simcere, sinaptica, TrueBinding, and Vaxxinity pharmaceutical, assessment, and investment companies. J.C. is the owner of the Neuropsychiatric Inventory. Y.Z., A.S., D.C., R.T.-K., J.F., and F.C. declare no competing interests.
